Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. (CRL) on Behalf of Stockholders and Encourages CRL Investors to Contact the Firm
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Charles River Laboratories International, Inc. (NYSE: CRL). Our investigation concerns whether Charles River has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On April 30, 2019, Charles River disclosed that a “highly sophisticated, well-resourced intruder” accessed its information system in mid-March 2019, and that data belonging to “approximately 1% of Charles River’s total number of clients” was “known to have been copied.”
On this news, Charles River’s share price fell by more than 3%, closing at $137.41 on May 1, 2019.
If you purchased or otherwise acquired Charles River shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Charles River please go to http://www.bespc.com/crl/. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.